Progyny IPO
Progyny is a leading fertility benefits management company that partners with employers to provide comprehensive fertility and family building benefits to their employees. The company manages fertility benefits including IVF, egg freezing, and other reproductive treatments through its network of high-quality providers. Investors value Progyny's position in the growing employer benefits market and its focus on improving outcomes while managing costs in fertility care.
What We Know
Progyny went public in October 2019, pricing its IPO at $13 per share and raising approximately $130 million. The company's public debut was well-received by investors, reflecting strong interest in the fertility benefits management market and Progyny's leading position in the space. Since going public, Progyny has continued to grow its client base and expand its network of fertility providers. The stock has generally performed well as the company has demonstrated consistent revenue growth and benefited from increased employer focus on comprehensive fertility benefits. Progyny trades on the NASDAQ under the ticker symbol PGNY.
Frequently Asked Questions
Has Progyny had an IPO?
Yes, Progyny completed its IPO in October 2019 and is publicly traded. The fertility benefits company has been public for several years and trades on the NASDAQ.
When is the Progyny IPO date?
Progyny's IPO took place in October 2019 when the company went public at $13 per share. The IPO has already occurred and was completed successfully.
How can I buy Progyny stock?
You can buy Progyny stock through any brokerage account as it trades publicly on the NASDAQ under the ticker symbol PGNY. The stock is available for purchase during regular market hours through most brokers.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts